CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.
1d
Barchart on MSNThis Dividend Stock Is Up 45% in 2025. Is It Too Late to Buy Shares Now?CVS Health (CVS) has made an impressive comeback in 2025, with its stock soaring 45% so far this year. This sharp rebound ...
CVS CEO David Joyner just finished his first full quarter at the helm. He spoke with Yahoo Finance about the conservative ...
Companies inform investors of possible business risks from Trump's government changes, tucking warnings into extensive "risk factor" sections of filings, contrasting with their publicly positive ...
CVS CEO David Joyner’s comments come as lawmakers on both sides of the aisle and President Donald Trump have signaled ...
CNBC on MSN9d
CVS shares pop 15% on big earnings beat, even as high medical costs drag down insurance unitIt caps off the first full quarter with David Joyner, a longtime CVS executive, as CEO of the troubled retail drugstore chain ...
CVS Health has named Ed DeVaney as president of its pharmacy benefit manager, CVS Caremark. | DeVaney has served as interim ...
CVS Health CEO David Joyner sees a way to create a more efficient healthcare professional network under the CVS umbrella.
Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...
Our drive to greater drug pricing transparency through innovation has never been more needed,” Ed DeVaney says.
3don MSN
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results